Form 4: BioCardia Director Acquires Stock Options

BioCardia, Inc. director Jay M. Moyes acquired 8,000 stock options with an exercise price of $1.20, vesting over one year.

Summary

• Jay M. Moyes, a Director at BioCardia, Inc., acquired 8,000 stock options on July 6, 2026.
• The stock options have an exercise price of $1.20 per share.
• These options are subject to vesting over a one-year period from the grant date, contingent on continued service.
• Following this transaction, Moyes beneficially owns 23,573 shares of common stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it indicates director commitment, but it's a standard option grant rather than a significant new investment or strategic move.

Positives

• Director acquisition of stock options signals confidence in the company's future prospects.
• The exercise price of $1.20 suggests a potential upside for the company if the stock price increases.
• The vesting schedule encourages continued commitment from the director.

Negatives

• The filing does not provide information on the current market price of the stock, making it difficult to assess the immediate value of the options.
• The acquisition is a grant of options, not a purchase of shares, meaning no immediate capital is injected into the company by the director.

Risks

• The value of the stock options is subject to market fluctuations and the company's performance.
• If the reporting person ceases to be a service provider before the vesting date, the options will not vest.

Future Outlook

The stock options are set to expire on July 6, 2036, and will vest over a one-year period from the grant date, subject to the reporting person's continued service.

Industry Context

StockSavvy.ai notes that insider grants of stock options are common in the biotechnology sector as a means to attract and retain key talent and align management interests with shareholder value.

Stakeholder Impact

• Shareholders: The grant of options could lead to future dilution if exercised, but also aligns director incentives with stock performance.
• Employees: May be seen as a positive sign of management confidence, potentially boosting morale.
• Management: The options provide a financial incentive for continued service and performance.

Next Steps

• The stock options will vest over one year, contingent on continued service.
• The options can be exercised up to their expiration date on July 6, 2036.

Key Dates

Keywords

BioCardia, BCDA, Form 4, Stock Options, Insider Trading, Director, Beneficial Ownership, SEC Filing